Carolina Martinez-Laperche
Overview
Explore the profile of Carolina Martinez-Laperche including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
455
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pavlova S, Malcikova J, Radova L, Bonfiglio S, Cowland J, Brieghel C, et al.
Hemasphere
. 2025 Jan;
9(1):e70065.
PMID: 39840379
In chronic lymphocytic leukemia, the reliability of next-generation sequencing (NGS) to detect variants ≤10% allelic frequency (low-VAF) is debated. We tested the ability to detect 23 such variants in 41...
2.
de la Iglesia-San Sebastian I, Lopez-Esteban M, Bastos-Oreiro M, Fernandez de Cordoba-Onate S, Gutierrez M, Carbonell D, et al.
Br J Haematol
. 2024 Dec;
206(1):195-203.
PMID: 39668521
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a transformative treatment for aggressive B-cell lymphomas (ABCL), However, about half of patients relapse, most of them early. This study investigates...
3.
Arguello-Tomas M, Mozas P, Albiol N, Lopez-Esteban M, Sierra J, Nomdedeu J, et al.
Cancer
. 2024 Sep;
131(1):e35552.
PMID: 39264834
Background: Overall, the prognosis of patients with chronic lymphocytic leukemia (CLL) in the early phase of the disease (Rai 0, Binet A) is favorable; some patients never require therapy. However,...
4.
Muniz P, Martinez-Garcia M, Bailen R, Chicano M, Oarbeascoa G, Trivino J, et al.
Front Immunol
. 2024 Sep;
15:1396284.
PMID: 39247183
Backgrounds: Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative therapy for hematological malignancies, it can be associated with relevant post-transplant complications. Several reports have shown that polymorphisms...
5.
Jimenez-Ubieto A, Martin-Munoz A, Poza M, Dorado S, Garcia-Ortiz A, Revilla E, et al.
Front Immunol
. 2024 Jan;
14:1349296.
PMID: 38268917
[This corrects the article DOI: 10.3389/fimmu.2023.1188818.].
6.
de la Iglesia-San Sebastian I, Carbonell D, Bastos-Oreiro M, Perez-Corral A, Bailen R, Chicano M, et al.
Transplant Cell Ther
. 2024 Jan;
30(3):306.e1-306.e12.
PMID: 38184148
Chimeric antigen receptor T cells (CAR-T) has emerged as a promising therapy, over 60% of patients fail to sustain a long-term response. The underlying factors that leads to the effectiveness...
7.
Jimenez-Ubieto A, Martin-Munoz A, Poza M, Dorado S, Garcia-Ortiz A, Revilla E, et al.
Front Immunol
. 2023 Sep;
14:1243241.
PMID: 37662957
[This corrects the article DOI: 10.3389/fimmu.2023.1188818.].
8.
Penas-Utrilla D, Perez-Lago L, Molero-Salinas A, Estevez A, Sanz A, Herranz M, et al.
Genome Med
. 2023 Jul;
15(1):57.
PMID: 37488638
Background: SARS-CoV-2 recombinants involving the divergent Delta and Omicron lineages have been described, and one of them, "Kraken" (XBB.1.5), has recently been a matter of concern. Recombination requires the coexistence...
9.
Rodriguez-Macias G, Briz O, Cives-Losada C, Chillon M, Martinez-Laperche C, Martinez-Arranz I, et al.
Cancers (Basel)
. 2023 Jun;
15(12).
PMID: 37370755
Despite its often low efficacy and high toxicity, the standard treatment for acute myeloid leukemia (AML) is induction chemotherapy with cytarabine and idarubicin. Here, we have investigated the role of...
10.
Jimenez-Ubieto A, Martin-Munoz A, Poza M, Dorado S, Garcia-Ortiz A, Revilla E, et al.
Front Immunol
. 2023 Jun;
14:1188818.
PMID: 37342332
Background: CART therapy has produced a paradigm shift in the treatment of relapsing FL patients. Strategies to optimize disease surveillance after these therapies are increasingly necessary. This study explores the...